Evaluation of gecacitinib vs hydroxyurea in patients with intermediate-2 or high-risk myelofibrosis: final analysis results from a randomized phase 3 study - Takeaways - MDSpire

Evaluation of gecacitinib vs hydroxyurea in patients with intermediate-2 or high-risk myelofibrosis: final analysis results from a randomized phase 3 study

  • By

  • Yi Zhang

  • Hu Zhou

  • Shanshan Suo

  • Junling Zhuang

  • Linhua Yang

  • Aili He

  • Qingchi Liu

  • Xin Du

  • Sujun Gao

  • Yarong Li

  • Yan Li

  • Yuqing Chen

  • Wen Wu

  • Huanling Zhu

  • Guangsheng He

  • Mei Hong

  • Qian Jiang

  • Zhongxing Jiang

  • Hongmei Jing

  • Jishi Wang

  • Na Xu

  • Lingling Yue

  • Cuiping Zheng

  • Zeping Zhou

  • Chenghao Jin

  • Xin Li

  • Lin Liu

  • Yajing Xu

  • Dengshu Wu

  • Feng Zhang

  • Jin Zhang

  • Liqing Wu

  • Hewen Yin

  • Binhua Lv

  • Zhijian Xiao

  • Jie Jin

  • December 18, 2024

  • 0 min

Share

  • 1

    Gecacitinib is a novel JAK and ACVR1 inhibitor showing superior efficacy over hydroxyurea in reducing spleen size in myelofibrosis patients.

  • 2

    The phase 3 trial ZGJAK016 demonstrated that gecacitinib improved quality of life and reduced anemia compared to hydroxyurea.

  • 3

    Myelofibrosis is characterized by severe anemia and splenomegaly, with a high incidence of anemia at diagnosis in Chinese patients.

  • 4

    Hydroxyurea's efficacy in treating myelofibrosis is limited, with many patients experiencing worsening anemia or cytopenia.

  • 5

    The study included patients aged 18 or older with intermediate-2 or high-risk myelofibrosis, randomized to receive either gecacitinib or hydroxyurea.

Original Source(s)

Evaluation of gecacitinib vs hydroxyurea in patients with intermediate-2 or high-risk myelofibrosis: final analysis results from a randomized phase 3 study

  • by Yi Zhang, Hu Zhou, Shanshan Suo, Junling Zhuang, Linhua Yang, Aili He, Qingchi Liu, Xin Du, Sujun Gao, Yarong Li, Yan Li, Yuqing Chen, Wen Wu, Huanling Zhu, Guangsheng He, Mei Hong, Qian Jiang, Zhongxing Jiang, Hongmei Jing, Jishi Wang, Na Xu, Lingling Yue, Cuiping Zheng, Zeping Zhou, Chenghao Jin, Xin Li, Lin Liu, Yajing Xu, Dengshu Wu, Feng Zhang, Jin Zhang, Liqing Wu, Hewen Yin, Binhua Lv, Zhijian Xiao, Jie Jin

  • December 18, 2024

Related Content

Health-economic evaluation of a novel personalized digital avatar-based anemia management software in hemodialysis patients

Fistulizing Crohn's disease

Luca Stocchi, M.D., a colorectal surgeon at Mayo Clinic in Florida, presents a surgical case involving a 53-year-old male with long-standing, fistulizing Crohn's disease. The patient had a prior open ileocolic resection and subsequently developed progressive weight loss and anemia.

  • January 5, 2026

  • 1 min
Triple-negative primary myelofibrosis: a comparative analysis of phenotype, genotype, and outcome